Literature DB >> 30403944

HCV-Associated Liver Fibrosis and HSD17B13.

Frédégonde About1, Laurent Abel2, Aurélie Cobat3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30403944     DOI： 10.1056/NEJMc1804638

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Down-Regulating the High Level of 17-Beta-Hydroxysteroid Dehydrogenase 13 Plays a Therapeutic Role for Non-Alcoholic Fatty Liver Disease.

Authors:  Meixi Wang; Jianrui Li; Hu Li; Biao Dong; Jing Jiang; Nannan Liu; Jiali Tan; Xuekai Wang; Lei Lei; Hongying Li; Han Sun; Mei Tang; Huiqiang Wang; Haiyan Yan; Yuhuan Li; Jiandong Jiang; Zonggen Peng
Journal:  Int J Mol Sci       Date:  2022-05-16       Impact factor: 6.208

2.  A closer look at the mysterious HSD17B13.

Authors:  X Charlie Dong
Journal:  J Lipid Res       Date:  2020-10-02       Impact factor: 5.922

3.  Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients.

Authors:  Carla De Benedittis; Mattia Bellan; Martina Crevola; Elena Boin; Matteo Nazzareno Barbaglia; Venkata Ramana Mallela; Paolo Ravanini; Elisa Ceriani; Stefano Fangazio; Pier Paolo Sainaghi; Michela Emma Burlone; Rosalba Minisini; Mario Pirisi
Journal:  Gastroenterol Res Pract       Date:  2020-04-24       Impact factor: 2.260

Review 4.  PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease.

Authors:  Xiaocheng Charlie Dong
Journal:  Front Med (Lausanne)       Date:  2019-12-17

Review 5.  Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.

Authors:  Shan Tang; Jing Zhang; Ting-Ting Mei; Wen-Yan Zhang; Su-Jun Zheng; Hai-Bin Yu
Journal:  BMC Gastroenterol       Date:  2021-12-20       Impact factor: 3.067

6.  A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease.

Authors:  Connor A Emdin; Mary E Haas; Amit V Khera; Krishna Aragam; Mark Chaffin; Derek Klarin; George Hindy; Lan Jiang; Wei-Qi Wei; Qiping Feng; Juha Karjalainen; Aki Havulinna; Tuomo Kiiskinen; Alexander Bick; Diego Ardissino; James G Wilson; Heribert Schunkert; Ruth McPherson; Hugh Watkins; Roberto Elosua; Matthew J Bown; Nilesh J Samani; Usman Baber; Jeanette Erdmann; Namrata Gupta; John Danesh; Danish Saleheen; Kyong-Mi Chang; Marijana Vujkovic; Ben Voight; Scott Damrauer; Julie Lynch; David Kaplan; Marina Serper; Philip Tsao; Josep Mercader; Craig Hanis; Mark Daly; Joshua Denny; Stacey Gabriel; Sekar Kathiresan
Journal:  PLoS Genet       Date:  2020-04-13       Impact factor: 5.917

7.  Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.

Authors:  Rafael Paternostro; Katharina Staufer; Stefan Traussnigg; Albert-Friedrich Stättermayer; Emina Halilbasic; Omar Keritam; Elias L Meyer; Judith Stift; Fritz Wrba; Bence Sipos; Ali Canbay; Martin Schlattjan; Elmar Aigner; Christian Datz; Felix Stickel; Clemens Schafmayer; Jochen Hampe; Stephan Buch; Gerhard Prager; Petra Munda; Mattias Mandorfer; Peter Ferenci; Michael Trauner
Journal:  Hepatol Int       Date:  2021-06-02       Impact factor: 6.047

Review 8.  Is HSD17B13 Genetic Variant a Protector for Liver Dysfunction? Future Perspective as a Potential Therapeutic Target.

Authors:  Takashi Motomura; Sriram Amirneni; Ricardo Diaz-Aragon; Lanuza A P Faccioli; Michelle R Malizio; Michael C Coard; Zehra N Kocas-Kilicarslan; Carla Frau; Nils Haep; Alina Ostrowska; Rodrigo M Florentino; Alejandro Soto-Gutierrez
Journal:  J Pers Med       Date:  2021-06-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.